Rockwell Medical stock, RMTI

Rockwell Medical stock: Q3 sales rise as guidance is withdrawn

Published on 11/20/2026 at 00:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Rockwell Medical stock faces a changed outlook after third-quarter results. The company withdrew its 2026 targets as it advances the Vantive transaction.

Quarterly results reshape outlook

  • Rockwell Medical reported stronger quarterly sales but a wider net loss for the period ended September 30, 2026.
  • The proposed Vantive transaction is expected to broaden the company beyond dialysis concentrates into equipment, water systems and related services.
  • Management withdrew its previously issued 2026 outlook as transaction-related costs affect planning.
Rockwell Medical stock, RMTI, third-quarter results, Vantive acquisition, dialysis products, Illustration mit AI erstellt.

Rockwell Medical reported stronger sales but a wider loss for the third quarter on Thursday, November 12, 2026. In a Business Wire release, the company said net sales for the three months ended September 30 reached 19.1 million US dollars, up 20 percent from the year-earlier period.

Sales growth meets deeper loss

Gross profit increased 37 percent to 3.1 million US dollars, while gross margin widened to 16 percent from 14 percent. The net loss, however, increased to 2.3 million US dollars from 1.8 million US dollars a year earlier, and adjusted EBITDA was negative 0.3 million US dollars compared with positive 50,000 US dollars.

For the first nine months, net sales rose 7 percent to 54.2 million US dollars. Gross profit increased 18 percent to 9.3 million US dollars, while the net loss widened to 5.1 million US dollars from 4.8 million US dollars.

Vantive deal changes the profile

Rockwell Medical is pursuing an equity and asset purchase agreement with Vantive Limited covering hemodialysis concentrates, machines including the AK-98, water treatment systems, consumables and technical services. The transaction also includes Vantive's manufacturing campus in Medolla, Italy. The combined business is projected to generate annual revenue between 400 million and 450 million US dollars, subject to completion of the proposed transaction and other conditions.

The U.S. Securities and Exchange Commission filing confirms that the November 12 report covered the quarter ended September 30. The company withdrew its previously issued 2026 guidance for net sales, gross margin, adjusted EBITDA and operating cash flow in connection with expected transaction-related and financing-related expenses.

Business and market position

Rockwell Medical develops, manufactures, commercializes and distributes hemodialysis products for dialysis providers worldwide. Its portfolio is centered on acid and bicarbonate concentrates, with the proposed Vantive transaction adding machines, water treatment systems, consumables and technical services. The company describes itself as the second-largest supplier of dialysis acid and bicarbonate concentrates in the United States and is seeking a broader global role.

Rockwell Medical company facts

  • Company: Rockwell Medical, Inc.
  • Ticker: RMTI
  • Exchange: Nasdaq Capital Market
  • Reporting period: Three months ended September 30, 2026
  • Net sales: 19.1 million US dollars
  • Net loss: 2.3 million US dollars
  • Proposed transaction: Vantive hemodialysis business and Medolla manufacturing campus

The proposed expansion places product breadth and execution at the center of the investment case, while the withdrawn 2026 outlook leaves near-term operating targets open. The S&P 500 provides the broader U.S. equity-market context for investors following the company.

Weitere Marktberichte finden Anleger im S&P 500 market environment.

Disclaimer...
en | boerse | 70538147 |